ILMN currently has a PEG ratio reading of 0.15 as of Jun 22, 2026. This metric factors in a PE of 29.24 with an earnings growth rate of 191.2%. When benchmarked against the trailing four-quarter average of 0.12, ILMN's PEG ratio shows a 28% increase.
A ten years lookback shows an average PEG ratio of 2.42 for Illumina. Compared to historical data, ILMN's 0.15 PEG ratio represents a decrease of 94%. Within the last ten years, the Apr 2022 quarter recorded the highest PEG value at 12.2. At 0.08, the Jun 2025 quarter showed the minimum PEG ratio in this period.
| Year | PEG ratio | PE ratio | Growth YoY |
|---|---|---|---|
| 2025 | 0.14 | 24.67 | 171.1% |
| 2024 | N/A | N/A | -4.8% |
| 2023 | N/A | N/A | 73.8% |
| 2023 | N/A | N/A | -652.3% |
| 2022 | 5.68 | 75.04 | 13.2% |
| 2021 | N/A | 82.59 | -34.2% |
| 2019 | 2.32 | 48.79 | 21% |
| 2018 | 3.92 | 52.97 | 13.5% |
| 2017 | 0.73 | 44.05 | 60.5% |
| 2017 | N/A | 41.44 | -3.1% |
| 2016 | 2.71 | 60.17 | 22.2% |
| 2014 | 0.45 | 72.11 | 161% |
| 2013 | N/A | 110.38 | -18.7% |
| 2012 | 0.59 | 44.51 | 75.7% |
| 2012 | N/A | 43.54 | -30.7% |
| Year | PEG ratio | PE ratio | Growth YoY |
|---|---|---|---|
| Mar 2026 | 0.11 | 21.32 | 191.2% |
| Dec 2025 | 0.14 | 24.67 | 171.1% |
| Sep 2025 | 0.14 | 20.51 | 144.9% |
| Jun 2025 | 0.08 | 11.97 | 141.4% |
| Mar 2025 | N/A | N/A | 25.8% |
| Dec 2024 | N/A | N/A | -4.8% |
| Sep 2024 | N/A | N/A | -40.1% |
| Jun 2024 | N/A | N/A | 28% |
| Mar 2024 | N/A | N/A | 71.4% |
| Dec 2023 | N/A | N/A | 73.8% |
| Oct 2023 | N/A | N/A | 73.1% |
| Jul 2023 | N/A | N/A | -33,137.5% |
| Apr 2023 | N/A | N/A | -721.1% |
| Jan 2023 | N/A | N/A | -652.3% |
| Oct 2022 | N/A | N/A | -531.2% |
Measured against past performance, ILMN's PEG ratio comes in under the 5 and 10-year averages.
Illumina's PEG of 0.15 is below the Healthcare sector and the industry average. In comparison with its Healthcare sector average of 0.55, Illumina's PEG is 73% lower.
Among its peer stocks TMO and A, ILMN's PEG ratio comes in lower.
| Stock name | PEG ratio | Market cap |
|---|---|---|
| ILMN Illumina Inc | 0.15 | $24.42B |
| A Agilent Technologies Inc | 1.1 | $35.72B |
| DGX Quest Diagnostics Inc | 1.46 | $21.43B |
| TMO Thermo Fisher Scientific Inc | 3.86 | $172.44B |
| PACB Pacific Biosciences Of California Inc | N/A | $409.99M |
| DHR Danaher Corp | N/A | $126.12B |
ILMN's Jun 22, 2026 PEG ratio comes in at 0.15.
Over the last 5 years, ILMN's PEG ratio has centered around 3.45.
In the last ten years, ILMN's peak PEG ratio of 12.2 was recorded in the Apr 2022 quarter.
ILMN currently has a PEG ratio 94% below its 10-year average.
Rapid earnings expansion combined with a reasonable valuation yields ILMN a PEG ratio of 0.15.
PEG equals PE divided by EPS growth rate (YoY TTM). As of Jun 22, 2026, Illumina carries a P/E ratio of 29.24. Earnings grew at 191.2% over the TTM period ending Mar 2026. Applying the formula, this yields a price to earnings growth ratio of 0.15. PEG RATIO(0.15) = PE RATIO(29.24) / EPS GROWTH(191.2%)
All PEG ratio stats are based on quarterly TTM periods, unless otherwise specified.